RECOMBINANT HUMAN CC10 FOR PREVENTION OF NEONATAL BPD

一种治疗和/或预防支气管炎的新蛋白质疗法 提出了早产儿的肺发育不良(BPD)。BPD是一种 对肺组织损伤的长期炎症反应始于 早产儿呼吸窘迫综合征的治疗 表面活性物质和高压氧。这种蛋白质被称为子宫红蛋白或 CC10被认为是一种天然的抗炎蛋白，存在于 呼吸道的细胞外液。然而，子宫红蛋白， 它通常存在于足月婴儿的肺部， 早产儿缺乏的。据报道，CC10抑制了 磷脂酶A2‘S的体外活性。这些酶有助于启动 细胞释放花生四烯酸引起的炎症反应 表面。花生四烯酸可引起几种炎症 化学物质；环状化合物、前列腺素和白三烯。的目标是 第一阶段是生产大约一克高纯度的CC10，这将 在新生儿呼吸窘迫综合征的动物模型上进行测试 和第二阶段的BPD。 建议的商业应用 这种蛋白质的潜在商业应用包括 炎症性疾病，包括新生儿呼吸窘迫 综合征和支气管肺发育不良。

A new protein therapy for the treatment and/or prevention of broncho- pulmonary dysplasia (BPD) in premature neonates is proposed. BPD is a long term inflammatory response to lung tissue damage initiated in the treatment of respiratory distress syndrome in premature infants, with surfactant and hyperbaric oxygen. The protein, called uteroglobin or CC10, is thought to be natural anti-inflammatory protein, present in the extracellular fluids of the respiratory tract. However, uteroglobin, which is normally present in the lungs of full term infants, is deficient in premature infants. CC10 has been reported to inhibit phospholipase A2's in vitro. These enzymes help initiate the inflammatory response by releasing arachidonic acid from cellular surfaces. Arachidonic acid gives rise to several inflammatory chemicals; cicosanoids, prostaglandins, and leukotrienes. The goal for Phase I is to produce about one gram of highly purified CC10, which will be tested in an animal model of neonatal respiratory distress syndrome and BPD in Phase II. PROPOSED COMMERCIAL APPLICATION The potential commercial applications for this protein include inflammatory disease conditions, including neonatal respiratory distress syndrome and broncho-pulmlonary dysplasia.